Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016

  • ID: 3802773
  • Report
  • 52 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BioCrea GmbH
  • Cerecor Inc.
  • Johnson & Johnson
  • Luc Therapeutics, Inc.
  • NeurOp, Inc
  • Novartis AG
  • MORE
Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016

Summary

‘Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016’, provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted pipeline therapeutics.

The report provides comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B)
- The report reviews Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BioCrea GmbH
  • Cerecor Inc.
  • Johnson & Johnson
  • Luc Therapeutics, Inc.
  • NeurOp, Inc
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Overview

Therapeutics Development

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Stage of Development

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Therapy Area

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Indication

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Companies

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Companies Involved in Therapeutics Development

BioCrea GmbH

Bristol-Myers Squibb Company

Cerecor Inc.

Johnson & Johnson

Luc Therapeutics, Inc.

NeurOp, Inc

Novartis AG

UCB S.A.

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Drug Profiles

CERC-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-100 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-10679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-11948 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radiprodil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NR2B for Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Dormant Projects

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Discontinued Products

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Featured News & Press Releases

Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model

Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect

Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder

Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum

Oct 02, 2014: NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate

Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study

Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder

Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate

Jun 28, 2010: Forest And Gedeon Richter Announce Phase II Study Results Of Radiprodil For Treatment Of Diabetic Peripheral Neuropathic Pain

Mar 11, 2010: Evotec Completes Clinical Part Of First Phase I Study Of EVT 103

Sep 08, 2009: Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist

Nov 29, 2005: Gedeon Richter And Forest Laboratories Expand Relationship With Two New Collaborations For CNS Compounds

Mar 24, 2004: Evotec Neurosciences License NMDA Receptor NR2B Subunit Selective Antagonists From Roche

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 52List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by BioCrea GmbH, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Cerecor Inc., H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Luc Therapeutics, Inc., H1 2016

Pipeline by NeurOp, Inc, H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by UCB S.A., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 43List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • BioCrea GmbH
  • Cerecor Inc.
  • Johnson & Johnson
  • Luc Therapeutics, Inc.
  • NeurOp, Inc
  • Novartis AG
  • MORE
Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Glutamate receptor subunit epsilon-2 or N-methyl D-aspartate receptor subtype 2B (NMDAR2B or NR2B) is a protein encoded by the GRIN2B gene. It is mediated by glycine. It acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them resulting in an irreversible neuronal death.

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively.

The author's latest report Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H1 2016, outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
BioCrea GmbH
Bristol-Myers Squibb Company
Cerecor Inc.
Johnson & Johnson
Luc Therapeutics, Inc.
NeurOp, Inc
Novartis AG
UCB S.A.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll